Literature DB >> 14504895

[Management of conjunctival malignant melanoma associated with primary acquired melanosis (PAM) using 0.02% mitomycin C eyedrops].

M J M Groh1, L M Holbach, B Kühnel, R M Conway, G O H Naumann.   

Abstract

BACKGROUND: The therapy of malignant diseases of the conjunctiva with local chemotherapy is an extension of the therapeutic options in this field. We report on our experience in the therapy of malignant melanomas of the conjunctiva associated with primary acquired melanosis (PAM). METHODS AND PATIENTS: Between March 1998 and April 2001, 13 patients with malignant melanoma of the conjunctiva associated with PAM (6 female; 7 male; mean age 57+/-13 years) were treated with local chemotherapy. The tumor was classified as stage pT2 (pN0, pM0) in seven patients, stage pT3 (pN0, pM0) in three patients and in the remaining three patients the lid was involved in the malignant process (pT4, pN0, pM0). Local chemotherapy (mitomycin C 0.02% eyedrops 5 times a day) was applied after incisional biopsies in 2 cycles for 14 days with a 14-day break. In 4 patients a third cycle was included.
RESULTS: Regression of the tumor was observed after completion of the therapy in all cases. Severe ocular or systemic secondary effects were not seen in our patients. Nine patients were without recurrence within the follow-up time. In three patients, a recurrence of the disease was observed. In these cases, the eyelid was involved in the process.
CONCLUSION: Local chemotherapy with mitomycin C is a useful option in the treatment of malignant melanomas of the conjunctiva associated with PAM if the tumor stage is pT3 or less. From our point of view the combination with incisional biopsy is of great benefit. Prognosis of conjunctival malignant melanomas involving the lid margin (pT4) is poor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504895     DOI: 10.1007/s00347-002-0765-z

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  14 in total

Review 1.  Tumors of the cornea and conjunctiva.

Authors:  K F Heffler
Journal:  Curr Opin Ophthalmol       Date:  1995-08       Impact factor: 3.761

2.  Use of mitomycin C in the treatment of conjunctival primary acquired melanosis with atypia.

Authors:  J Frucht-Pery; J Pe'er
Journal:  Arch Ophthalmol       Date:  1996-10

3.  Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations.

Authors:  H Demirci; S A McCormick; P T Finger
Journal:  Arch Ophthalmol       Date:  2000-07

4.  Topical chemotherapy for conjunctival melanoma.

Authors:  P T Finger; M S Milner; S A McCormick
Journal:  Br J Ophthalmol       Date:  1993-11       Impact factor: 4.638

Review 5.  Antimetabolites in ocular surface neoplasia.

Authors:  P A Majmudar; R J Epstein
Journal:  Curr Opin Ophthalmol       Date:  1998-08       Impact factor: 3.761

6.  Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience.

Authors:  J Frucht-Pery; J Sugar; J Baum; J E Sutphin; J Pe'er; H Savir; E J Holland; D M Meisler; J A Foster; R Folberg; Y Rozenman
Journal:  Ophthalmology       Date:  1997-12       Impact factor: 12.079

7.  Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia.

Authors:  M W Wilson; J L Hungerford; S M George; S A Madreperla
Journal:  Am J Ophthalmol       Date:  1997-09       Impact factor: 5.258

8.  Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia.

Authors:  P T Finger; G Czechonska; S Liarikos
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

9.  Long-term results of cryotherapy on malignant epithelial tumors of the conjunctiva.

Authors:  G Peksayar; M K Soytürk; M Demiryont
Journal:  Am J Ophthalmol       Date:  1989-04-15       Impact factor: 5.258

10.  Mitomycin C therapy for corneal intraepithelial neoplasia.

Authors:  J Frucht-Pery; Y Rozenman
Journal:  Am J Ophthalmol       Date:  1994-02-15       Impact factor: 5.258

View more
  4 in total

1.  [Classification of biomedical research reports as a reference for evidence-based medicine in ophthalmology. A survey considering as example the journal Der Ophthalmologe].

Authors:  H P N Scholl; M Fleckenstein; T U Krohne; F G Holz
Journal:  Ophthalmologe       Date:  2005-12       Impact factor: 1.059

2.  [Differential diagnosis and treatment options for conjunctival tumors].

Authors:  L M Holbach; P Pogorelov; F E Kruse
Journal:  Ophthalmologe       Date:  2007-06       Impact factor: 1.059

Review 3.  [Topical Mitomycin C as a therapy of conjunctival tumours].

Authors:  M Schallenberg; N Niederdräing; K-P Steuhl; D Meller
Journal:  Ophthalmologe       Date:  2008-08       Impact factor: 1.059

Review 4.  [Adjuvant therapy and interdisciplinary follow-up care of conjunctival melanoma].

Authors:  L M Heindl; K R Koch; M Schlaak; C Mauch; C Cursiefen
Journal:  Ophthalmologe       Date:  2015-11       Impact factor: 1.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.